Safety and Efficacy of VSJ-110 in the Treatment of Allergic Conjunctivitis in Adults With a History of Ocular Allergies

Last updated: September 9, 2025
Sponsor: Vanda Pharmaceuticals
Overall Status: Completed

Phase

2

Condition

Allergies & Asthma

Allergy (Pediatric)

Eye Disorders/infections

Treatment

Placebo

VSJ-110

Clinical Study ID

NCT04622345
VP-VSJ-110-2101
  • Ages > 18
  • All Genders

Study Summary

The purpose of this study is to determine the safety and efficacy of VSJ-110 compared to placebo in the treatment of allergic conjunctivitis using an antigen challenge model

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • At least 18 years of age of either gender and any race

  • Able to provide written informed consent and sign the HIPAA form

  • Willing and able to follow all instructions and attend all study visits

Exclusion

Exclusion Criteria:

  • Able and willing to avoid all disallowed medications during washout and study period

Study Design

Total Participants: 47
Treatment Group(s): 2
Primary Treatment: Placebo
Phase: 2
Study Start date:
November 21, 2020
Estimated Completion Date:
June 28, 2021

Connect with a study center

  • Vanda Investigational Site

    Andover, Massachusetts 01810
    United States

    Site Not Available

  • Vanda Investigational Site

    Andover 4929055, Massachusetts 6254926 01810
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.